Causes of Uterine Polyps
Uterine polyps (endometrial polyps) are primarily caused by hormonal imbalances—particularly excess estrogen exposure—combined with genetic alterations, chronic inflammation, and local immune dysregulation.
Primary Etiologic Mechanisms
Hormonal Factors (Most Significant)
Excess estrogen is the dominant driver of endometrial polyp formation. The mechanisms include:
- Unopposed estrogen exposure: Whether endogenous (obesity, early menarche, late menopause, anovulation) or exogenous (hormone replacement therapy without progesterone) 1
- Progesterone deficiency: Local progesterone receptor dysfunction leads to unchecked endometrial proliferation 2
- Tamoxifen use: Selective estrogen receptor modulator activity stimulates endometrial growth 3
- Polycystic ovarian syndrome (PCOS): Creates chronic anovulation and estrogen dominance 4
Genetic and Molecular Alterations
Chromosomal rearrangements affecting HMGA1 and HMGA2 genes occur in 74% of endometrial polyps, representing the most common genetic abnormality 5. These include:
- Rearrangements involving LRMDA, RAD51B, TRAF3IP2, and 7p15.2 as recurrent partners
- Overexpression of HMGA1, HMGA2, and downstream target PLAG1
- Novel recurrent mutations in UBE2A (a newly identified candidate driver gene)
- Low-allelic fraction mutations in cancer-related genes (KRAS, PIK3CA, PIK3R1, PTEN) 5
Inflammatory and Immune Mechanisms
Local immune imbalance with hypofunctional NK cells creates an environment permissive for polyp development 2. Contributing factors include:
- Chronic endometritis with focal infiltrates of leukocytes (CD45), macrophages (CD68), plasmacells (CD138), and NK cells (CD56)
- Microbial dysbiosis and altered endometrial microbiota 6
- Viral and fungal infestations in the setting of immune dysfunction 2
- Oxidative stress and chronic inflammation 6
Risk Factors
Modifiable Risk Factors
- Obesity: Creates peripheral estrogen conversion and metabolic syndrome 4, 6
- Metabolic syndrome components: Hypertension, diabetes mellitus, hypertriglyceridemia 4
- Exogenous hormone use: Unopposed estrogen therapy, tamoxifen 3
Non-Modifiable Risk Factors
- Age: Increasing age is strongly associated with polyp development 3
- Nulliparity and infertility: Reduced progesterone exposure over lifetime 4
- Early menarche/late menopause: Extended lifetime estrogen exposure 4
Clinical Pathogenesis Variations
The evidence identifies distinct pathogenic subtypes 2:
- Isolated polyps: Primarily hormonal (progesterone deficiency) with genetic alterations
- Micropolyps: Predominantly inflammatory with active chronic endometritis
- Combined polyps with micropolyps: Mixed hormonal and inflammatory mechanisms with severe immune dysfunction
Important Clinical Caveats
- While most polyps are benign, approximately 5% may undergo hyperplastic or malignant transformation 3
- Incomplete surgical resection is a major risk factor for recurrence 6
- The multifactorial nature means no single mechanism explains all cases—polyps arise through interaction of chromosomal changes, genetic variants, hormonal imbalances, and immune dysregulation 7
- Genetic factors (Lynch syndrome, Cowden syndrome) account for a small subset but carry higher malignancy risk 8